Dongshan Yang

Dr. Dongshan Yang

Center for Advanced Models and Translational Sciences and Therapeutics, University of Michigan Medical Center, Ann Arbor, MI 48109, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2010 in Cell Stem Cell
Verified
Journal Article
Closed access
RLRonghui Li
Ronghui Li
JLJialiang Liang
Jialiang Liang
SNSu Ni
Su Ni
TZTing Zhou
Ting Zhou
XQXiaobing Qing
Xiaobing Qing
DPDuanqing Pei
Duanqing Pei

28 January 2016 in Nature Communications
Verified
Journal Article
Open access
JSJun Song
Jun Song
DYDongshan Yang
Dongshan Yang
JXJie Xu
Jie Xu
TZTianqing Zhu
Tianqing Zhu
YCY. Eugene Chen
Y. Eugene Chen
JZJifeng Zhang
Jifeng Zhang
Zinc-finger nuclease, transcription activator-like effector nuclease and CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) are becoming major tools for genome editing. Importantly, knock-in in several non-rodent species has been finally achieved thanks to these customizable nucleases; yet the rates remain to be further improved. We hypothesize that inhibiting non-homologous end joining (NHEJ) or enhancing homology-directed repair (HDR) will improve the nuclease-mediated knock-in efficiency. Here we show that the in vitro application of an HDR enhancer, RS-1, increases the knock-in efficiency by two- to five-fold at different loci, whereas NHEJ inhibitor SCR7 has minimal effects. We then apply RS-1 for animal production and have achieved multifold improvement on the knock-in rates as well. Our work presents tools to nuclease-mediated knock-in animal production, and sheds light on improving gene-targeting efficiencies on pluripotent stem cells.

2 December 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
OROren Rom
Oren Rom
YLYuhao Liu
Yuhao Liu
ZLZhipeng Liu
Zhipeng Liu
YZYing Zhao
Ying Zhao
JWJianfeng Wu
Jianfeng Wu
YCY. Eugene Chen
Y. Eugene Chen
Nonalcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH) has reached epidemic proportions with no pharmacological therapy approved. Lower circulating glycine is consistently reported in patients with NAFLD, but the causes for reduced glycine, its role as a causative factor, and its therapeutic potential remain unclear. We performed transcriptomics in livers from humans and mice with NAFLD and found suppression of glycine biosynthetic genes, primarily alanine-glyoxylate aminotransferase 1 (AGXT1). Genetic (Agxt1−/− mice) and dietary approaches to limit glycine availability resulted in exacerbated diet-induced hyperlipidemia and steatohepatitis, with suppressed mitochondrial/peroxisomal fatty acid β-oxidation (FAO) and enhanced inflammation as the underlying pathways. We explored glycine-based compounds with dual lipid/glucose-lowering properties as potential therapies for NAFLD and identified a tripeptide (Gly-Gly-L-Leu, DT-109) that improved body composition and lowered circulating glucose, lipids, transaminases, proinflammatory cytokines, and steatohepatitis in mice with established NASH induced by a high-fat, cholesterol, and fructose diet. We applied metagenomics, transcriptomics, and metabolomics to explore the underlying mechanisms. The bacterial genus Clostridium sensu stricto was markedly increased in mice with NASH and decreased after DT-109 treatment. DT-109 induced hepatic FAO pathways, lowered lipotoxicity, and stimulated de novo glutathione synthesis. In turn, inflammatory infiltration and hepatic fibrosis were attenuated via suppression of NF-κB target genes and TGFβ/SMAD signaling. Unlike its effects on the gut microbiome, DT-109 stimulated FAO and glutathione synthesis independent of NASH. In conclusion, impaired glycine metabolism may play a causative role in NAFLD. Glycine-based treatment attenuates experimental NAFLD by stimulating hepatic FAO and glutathione synthesis, thus warranting clinical evaluation.

1 February 2014 in Journal of Molecular Cell Biology
Verified
Journal Article
Open access
PDF file
DYDongshan Yang
Dongshan Yang
JXJie Xu
Jie Xu
TZTianqing Zhu
Tianqing Zhu
Jianglin FanJianglin Fan
Jianglin Fan
LLLiangxue Lai
Liangxue Lai
YCY. Eugene Chen
Y. Eugene Chen

21 July 2010 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
DYDongshan Yang
Dongshan Yang
CWChuan-En Wang
Chuan-En Wang
BZBentian Zhao
Bentian Zhao
WLWei Li
Wei Li
ZOZhen Ouyang
Zhen Ouyang
XLXiao-Jiang Li
Xiao-Jiang Li
Neurodegeneration is a hallmark of many neurological diseases, including Alzheimer's, Parkinson's and the polyglutamine diseases, which are all caused by misfolded proteins that accumulate in neuronal cells of the brain. Although apoptosis is believed to contribute to neurodegeneration in these cases, genetic mouse models of these diseases often fail to replicate apoptosis and overt neurodegeneration in the brain. Using nuclear transfer, we generated transgenic Huntington's disease (HD) pigs that express N-terminal (208 amino acids) mutant huntingtin with an expanded polyglutamine tract (105Q). Postnatal death, dyskinesia and chorea-like movement were observed in some transgenic pigs that express mutant huntingtin. Importantly, the transgenic HD pigs, unlike mice expressing the same transgene, displayed typical apoptotic neurons with DNA fragmentation in their brains. Also, expression of mutant huntingtin resulted in more neurons with activated caspase-3 in transgenic pig brains than that in transgenic mouse brains. Our findings suggest that species differences determine neuropathology and underscore the importance of large mammalian animals for modeling neurological disorders.

19 April 2011 in Cell Research
Verified
Journal Article
Closed access
PDF file
DYDongshan Yang
Dongshan Yang
Huaqiang YangHuaqiang Yang
Huaqiang Yang
WLWei Li
Wei Li
BZBentian Zhao
Bentian Zhao
ZOZhen Ouyang
Zhen Ouyang
LLLiangxue Lai
Liangxue Lai